Drug Database
Back to search

Ireland· IE-PA-EU/1/22/1651/001

EVUSHELD 150 mg + 150 mg solution for injection

A tixagevimab und cilgavimab product containing tixagevimab + cilgavimab, registered in Ireland by AstraZeneca AB. The same ATC class is registered in 3 of our 19 countries.

ATC J06BD03

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedEVUSHELD 150 mg + 150 mg solution for…ATCJ06BD03REGISTER NO.IE-PA-EU/1/22/1651/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tixagevimab + cilgavimabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tixagevimab und cilgavimab is registered in 3 of 19 countries.

Countries holding a registration under ATC J06BD03 (tixagevimab und cilgavimab), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 2 of them publish a price we can compare per daily dose
Search tixagevimab und cilgavimab products by name

Tixagevimab und cilgavimab · ATC J06BD03

3 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Ireland
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Tixagevimab + Cilgavimab
Manufacturer
AstraZeneca AB
Country
Ireland (IE)
ATC code
J06BD03
ATC class
Tixagevimab und Cilgavimab
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/22/1651/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tixagevimab und cilgavimab in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tixagevimab und cilgavimab products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ab938e92-ae2b-4676-89c9-04cd458ff794
GET /v1/drugs/ab938e92-ae2b-4676-89c9-04cd458ff794?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "routes": [
    "Intramuscular use"
  ],
  "source": "hpra",
  "atc_all": [
    "J06B",
    "J06BD03"
  ],
  "strength": null,
  "pa_number": "EU/1/22/1651/001",
  "substances": [
    "Tixagevimab",
    "Cilgavimab"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "25/03/2022",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about tixagevimab und cilgavimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console